Citizens Maintains Market Outperform on IRulya Therapeutics, Raises Price Target to $86
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citizens analyst Jonathan Wolleben maintains IRulya Therapeutics (NASDAQ:IRLA) with a Market Outperform and raises the price target from $77 to $86.
Citizens analyst Jonathan Wolleben maintains IRulya Therapeutics (NASDAQ:IRLA) with a Market Outperform and raises the price target from $77 to $86.
